Infliximab (Remsima®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000592
English
Authors' recommendations:
Infliximab (Remsima®) is recommended as an option for restricted use within NHS Wales. Infliximab (Remsima® should be prescribed within its licensed indications in accordance with NICE or AWMSG guidance for infliximab (Remicade®), the reference product. Infliximab (Remsima®)should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2254
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antibodies, Monoclonal
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.